BLUE Logo

bluebird bio, Inc. (BLUE) 

NASDAQ
Market Cap
$67.9M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
462 of 775
Rank in Industry
243 of 433

Largest Insider Buys in Sector

BLUE Stock Price History Chart

BLUE Stock Performance

About bluebird bio, Inc.

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of …

Insider Activity of bluebird bio, Inc.

Over the last 12 months, insiders at bluebird bio, Inc. have bought $0 and sold $83,819 worth of bluebird bio, Inc. stock.

On average, over the past 5 years, insiders at bluebird bio, Inc. have bought $0 and sold $954,866 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 19,364 shares for transaction amount of $1M was made by Leschly Nick (President and CEO) on 2015‑12‑08.

List of Insider Buy and Sell Transactions, bluebird bio, Inc.

2024-09-30SalePresident and CEO
34,780
0.0189%
$0.53$18,270-7.26%
2024-09-30SaleSee Remarks
1,006
0.0005%
$0.53$529-7.26%
2024-06-03SaleSee Remarks
3,834
0.002%
$0.97$3,726-40.48%
2024-03-04SalePresident and CEO
6,095
0.0031%
$1.53$9,311-38.63%
2024-03-04SaleSee Remarks
4,573
0.0023%
$1.53$6,986-38.63%
2024-03-01SaleChief Medical Officer
6,770
0.0034%
$1.53$10,342-39.65%
2024-02-05SalePresident and CEO
1,879
0.0008%
$0.90$1,696+6.20%
2024-02-05SaleSee Remarks
2,714
0.0012%
$0.90$2,449+6.20%
2024-02-05SaleChief Business & Legal Officer
5,217
0.0023%
$0.90$4,708+6.20%
2024-01-05SalePresident and CEO
3,162
0.0016%
$1.43$4,520-30.72%
2024-01-05SaleChief Medical Officer
597
0.0003%
$1.42$845-30.72%
2023-12-06SaleChief Financial Officer
4,526
0.0039%
$4.52$20,437-78.99%
2023-11-03SalePresident and CEO
807
0.0007%
$3.17$2,555-69.54%
2023-11-02SaleChief Medical Officer
2,343
0.0021%
$2.98$6,975-65.25%
2023-09-05SaleSee Remarks
922
0.0009%
$3.79$3,493-65.15%
2023-08-10SalePresident and CEO
16,929
0.0168%
$3.54$59,956-58.88%
2023-06-02SaleSee Remarks
4,130
0.0039%
$3.50$14,451-20.39%
2023-01-11Saledirector
4,290
0.0041%
$7.80$33,480-55.56%
2023-01-11SalePresident and CEO
3,178
0.003%
$7.80$24,802-55.56%
2023-01-11SaleChief Medical Officer
557
0.0005%
$7.80$4,347-55.56%

Insider Historical Profitability

54.67%
Leschly Nickdirector
280149
0.1441%
$0.35149<0.0001%
MARAGANORE JOHNdirector
5843
0.003%
$0.3524+99.03%
Schenkein David Pdirector
3176
0.0016%
$0.3512+30.47%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$19.43M7.9715.18M+68.97%+$7.93M<0.0001
The Vanguard Group$13.44M5.5210.5M+19.64%+$2.21M<0.0001
Granahan Investment Management$9.87M4.057.71M-4.53%-$468,515.830.35
Ameriprise Financial$8.18M3.366.39M+131.96%+$4.65M<0.01
Millennium Management LLC$7.99M3.286.24M+82.78%+$3.62M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.